The URL can be used to link to this page

Browse Search

Home My WebLink About20211958.tiffRESOLUTION RE: APPROVE ACKNOWLEDGEMENT LETTER AND STATEMENT OF WORK FOR ELC ENHANCING DETECTION EXPANSION (ELC 2) FOR COVID-19 SUPPLEMENTAL FUNDS AND AUTHORIZE CHAIR TO SIGN WHEREAS, the Board of County Commissioners of Weld County, Colorado, pursuant to Colorado statute and the Weld County Home Rule Charter, is vested with the authority of administering the affairs of Weld County, Colorado, and WHEREAS, the Board has been presented with an Acknowledgement Letter and Statement of Work for ELC Enhancing Detection Expansion (ELC 2) for COVID-19 Supplemental Funds between the County of Weld, State of Colorado, by and through the Board of County Commissioners of Weld County, on behalf of the Department of Public Health and Environment, and the Colorado Department of Public Health and Environment, commencing January 14, 2021, and ending July 31, 2023, with further terms and conditions being as stated in said acknowledgement letter and statement of work, and WHEREAS, after review, the Board deems it advisable to approve said acknowledgement letter and statement of work, copies of which are attached hereto and incorporated herein by reference. NOW, THEREFORE, BE IT RESOLVED by the Board of County Commissioners of Weld County, Colorado, that the Acknowledgement Letter and Statement of Work for ELC Enhancing Detection Expansion (ELC 2) for COVID-19 Supplemental Funds between the County of Weld, State of Colorado, by and through the Board of County Commissioners of Weld County, on behalf of the Department of Public Health and Environment, and the Colorado Department of Public Health and Environment, be, and hereby is, approved. BE IT FURTHER RESOLVED by the Board that the Chair be, and hereby is, authorized to sign said acknowledgement letter. CC :14L tr ) 07/.22_421 2021-1958 BC0054 HL0053 ACKNOWLEDGEMENT LETTER AND STATEMENT OF WORK FOR ELC ENHANCING DETECTION EXPANSION (ELC 2) FOR COVID-19 SUPPLEMENTAL FUNDS PAGE 2 The above and foregoing Resolution was, on motion duly made and seconded, adopted by the following vote on the 14th day of July, A.D., 2021, nunc pro tunc January 14, 2021. BOARD OF COUNTY COMMISSIONERS WELD COUNTY, COLORADO ATTEST: delft/LA) �Cl+[�►�� Weld County Clerk to the Board BY: Deputy Clerk to the Boar APP' ! . ED A y A orney Lori Saine Date of signature: 07/20/2( es, Pro -T 2021-1958 BC0054 HL0053 1Qflte1c-- -s-D $* (-I °I Co I Memorandum TO: FROM: DATE: SUBJECT: Steve Moreno, Chair Board of County Commissioners Mark Lawley, Executive Director Department of Public Health & Environment June 28, 2021 ELC Enhancing Detection Expansion for COVID-19 with CDPHE — Round 2 Acknowledgement Letter For the Board's approval is an Acknowledgement Letter for ELC Enhancing Detection Expansion (ELC2) that is being requested by the Colorado Department of Public Health and Environment (CDPHE) to provide the Weld County Department of Public Health and Environment (WCDPHE) with additional funding for COVID-19 activities related to disease surveillance, case investigation, contact tracing and testing. If the Board approves this additional funding opportunity, the Health Department will primarily expend the funds on COVID-19 staff performing contact tracing and case investigation activities. In addition, we are recommending purchase of a PCR machine, and associated supplies, that can perform testing for COVID-19, but that can also be used for additional new tests in our laboratory including viral- influenza, other types of coronavirus, rhinovirus, bacterial-pertussis (whooping cough) and pneumonia. The remaining budget covers expenditures supplemental to these primary activities including, but not limited to, items such as supplies, small items of equipment, data analysis software, travel and training. This second round of ELC funding is an expansion of COVID-19 funding that commenced in June of 2020. The period for the activities described in the statement of work allows for reimbursements backdating to January 1, 2021, and continuing through July 31, 2023, with funding not to exceed $5,937,731. Assistant Weld County Attorney, Karin McDougal, has reviewed this Acknowledgement Letter and the ancillary documents indicated in it and determined that its contents are acceptable. The Board approved placement of this Acknowledgement Letter and the ancillary documents on the Board's agenda via pass -around dated June 25, 2021. I recommend approval of this Acknowledgement Letter to receive the 2nd round of ELC funding. 2021-1958 0-1/ 107 I-HL0053 c0059 BOARD OF COUNTY COMMISSIONERS PASS -AROUND REVIEW RE: ELC Enhancing Detection Expansion for COVID-19 with CDPHE — Acknowledgment Letter DEPARTMENT: PUBLIC HEALTH & ENVIRONMENT PERSON REQUESTING: Mark Lawley, Executive Director DATE: June 25, 2021 Brief description of the problem/issue: For the Board's review and signature is an Acknowledgement Letter for ELC Enhancing Detection Expansion (ELC2) that is being requested by the Colorado Department of Public Health and Environment (CDPHE) to provide the Weld County Department of Public Health and Environment (WCDPHE) with additional funding for COVID-19 activities related to disease surveillance, case investigation, contact tracing and testing. If the Board approves this additional funding opportunity, the Health Department will primarily expend the funds on COVID-19 staff performing contact tracing and case investigation activities. In addition, we are recommending purchase of a PCR machine, and associated supplies, that can perform testing for COVID-19, but that can also be used for additional new tests in our laboratory including viral- influenza, other types of coronavirus, rhinovirus, bacterial-pertussis (whooping cough) and pneumonia. The remaining budget covers expenditures supplemental to these primary activities including, but not limited to, items such as supplies, small items of equipment, data analysis software, travel and training. This second round of ELC funding is an expansion of COVID-19 funding that commenced in June of 2020. The period for the activities described in the statement of work allows for reimbursements backdating to January 1, 2021, and continuing through July 31, 2023, with funding not to exceed $5,937,731. Assistant Weld County Attorney, Karin McDougal, has reviewed this Acknowledgment Letter and the ancillary documents indicated in it and determined that its contents are acceptable. What options exist for the Board? (include consequences, impacts, costs, etc. of options): Signing this Acknowledgment Letter will provide additional funding to Weld County for continuation of COVID- 19 activities that the county is currently performing and is anticipated to continue performing through the end of the grant period. The WCDPHE provides COVID-19 support to numerous organizations, businesses, residents, schools and long-term care facilities in Weld County. Support is provided through assistance with education, case investigation, contact tracing and testing support activities. These activities have been the county's primary control measure for COVID-19. If signing this Acknowledgement Letter is not approved, WCDPHE may not receive additional external funding to provide COVID-19 activities in Weld County and these services may then become 100% county funded at some point during this pandemic. Recommendation: I recommend approval for the Chair to sign the Acknowledgement Letter to receive the 2nd round of ELC funding. Perry L. Buck Mike Freeman Scott K. James, Pro -Tern Steve Moreno, Chair Lori Saine Approve Schedule Recommendation Work Session Other/Comments: WELD COUNTY DEPARTMENT ENT OF PUBLIC HEALTH AND ENVIRONMENT 1555 North 17th Avenue, Greeley, CO 80631 www.weldhealth.erg Toe Organization Name: Subject: Dear Ms. Comstock: Nicole Comstock Weld County Department of Public Health and Environment Acknowledgement letter for ELC Enhancing Detection Expansion This is to acknowledge that I have received, reviewed, and understand the requirements in the ELC Enhancing Detection Expansion (ELC 2) Scope of Work, Allowability Roadmap and Federal Provisions. The federal funding received will be in support of the scope of work referenced herein and will be spent in accordance with the legislation and programmatic guidance. Steve Moreno Chair, Weld County Board of County Commissioners Health Administration Vital Records Tele: 970-304-6410 Fax: 970-304-6412 Public Health & Clinical Services Tele: 970-304-6420 Fax: 970-304-6416 J Environmental Health Services Tele: 970-304-6415 Fax: 970-304-6411 4 z021 Communication, Education & Planning Tele: 970-304-6470 Fax: 970-304-6452 Public Health 93-3) ELC Enhancing Detection COVID-19 Supplemental Funds (Round 2) to LPHAs: Statement of Work I. Project Description: This project serves to control the spread of COVID-19 in Colorado. The COVID-19 pandemic has resulted in an unprecedented public health response worldwide. The project will strengthen and support local public health agencies responding to COVID-19 by funding personnel to perform critical containment activities, such as disease surveillance, case investigation, contact tracing, and testing, based on jurisdictional needs. The project also supports local responses to COVID-19 outbreaks, infection prevention efforts at health care and other settings, and promotes health equity aspects of the response. The project benefits all Coloradans by providing support to every local public health agency working on behalf of Colorado communities. The project covers activities starting on January 14, 2021, through July 31, 2023. The funding for this effort is from the Centers for Disease Control and Prevention (CDC) Epidemiology and Laboratory Capacity (ELC) cooperative agreement titled "Enhancing Detection Through Coronavirus Response and Relief Supplemental Funds"; activities outlined in this statement of work are in line with guidance CDC provided with the funding source and builds upon the first round of ELC funding distributed to local public health agencies in June 2020. II. Definitions: 1. CDC - Centers for Disease Control and Prevention 2. CDPHE - Colorado Department of Public Health and Environment 3. CEDRS - Colorado Electronic Disease Reporting System 4. Dr. Justina - The statewide COVID-19 case and contact surveillance system; this system shares case data with CEDRS 5. Colorado COVID-19 Case and Outbreak Definitions - Can be found at the following website and will be updated as needed: https: //docs.google.corn /document/d/1 e-IWLtzJNCgI2gzPONGvEASGgse 85WuBmcToc9ev-74/edit?usp=sharing 6. Outbreak line lists - Electronic lists of probable and confirmed cases containing demographic, illness, and exposure information for each case. A CDPHE developed template is available. 7. LPHA - Local public health agency 1 8. Quarterly time frames - For the purpose of submitting the quarterly online survey, quarters are defined as: 1. Quarter 1: July - September 2. Quarter 2: October - December 3. Quarter 3: January - March 4. Quarter 4: April - June III. Work Plan: Goal #1: Control the spread of COVID-19 in Colorado. Objective #1: No later than the expiration date of the contract, support public health personnel conducting epidemiological response activities for COVID-19. Primary Activity #1 The Contractor shall use funding to support personnel to work on COVID-19 epidemiological response activities. Sub -Activities #1 1. The Contractor shall prepare a plan identifying the COVID-19 epidemiological response activities that require personnel funding support based on the jurisdictional needs. 2. The Contractor shall prepare a capacity plan outlining local public health agency implementation steps to be the primary provider of all COVID-19 case investigation, contact tracing, and outbreak investigation activities in non -state -run facilities for their jurisdiction by January 2, 2022. Primary Activity #2 The Contractor shall prepare a project budget that covers the time frame through July 31, 2023. Sub -Activities #2 1. The Contractor shall revise the budget annually. Primary Activity #3 The Contractor shall complete the funding acknowledgement letter. 2 Primary Activity #4 The Contractor shall implement the COVID-19 epidemiological response activities outlined in the plan approved by CDPHE. Sub Activities #4 1. The Contractor shall complete the quarterly online survey on epidemiological response activities being performed. 2. The Contractor shall have a staff member attend, or watch the recording, of the statewide CDPHE/local public health agency COVID-19 webinars. Primary Activity #5 The Contractor shall prepare a COVID-19 testing plan for the jurisdiction that describes testing options and how the Contractor is ensuring access to testing. Primary Activity #6 The Contractor shall investigate outbreaks of COVID-19. Sub Activities #6 1. The Contractor shall provide initial outbreak reports to CDPHE. 2. The Contractor shall provide outbreak line lists to CDPHE. 3. The Contractor shall provide outbreak final reports to CDPHE. Objective #2: No later than the expiration date of the contract, increase knowledge of infection prevention and control within the jurisdiction. Primary Activity #1 The Contractor shall distribute ventilation guidance and toolkit information to residential care facilities in their jurisdiction. Sub Activities #1 The Contractor shall track which residential care facilities received the ventilation guidance and toolkit. Primary Activity #2 The Contractor shall identify an individual to function as an infection prevention liaison with CDPHE. Objective #3: No later than the expiration date of the contract, incorporate health equity principles into COVID-19 epidemiological, testing, and vaccination response activities. 3 Primary Activity #1 The Contractor shall incorporate health equity principles into COVID-19 epidemiological, testing, and vaccination response activities. Standards and Requirements 1. The content of electronic documents located on CDPHE and non-CDPHE websites and information contained on CDPHE and non-CDPHE websites may be updated periodically during the contract term. The contractor shall monitor documents and website content for updates and comply with all updates. 2. The Contractor shall comply with allowability of expenditures as listed in the CDPHE COVID-19 ELC round 2; Allowable costs for funding source can be found on the following website: https: //sites400gle.com /state.co.us/covid-19fiscalrespons e/elc-enhancing-detection-expansion . The content of this website is incorporated and made part of this contract by reference. 3. CDPHE will provide the template for the plan for identifying the COVID-19 epidemiological activities and capacity plan for the LPHA being the primary provider of case investigation, contact tracing, and outbreak investigation activities in non -state -run facilities no later than five (5) business days after contract execution. 4. The Contractor shall consult with CDPHE if they are unable to meet the target for completed case interviews. This target is 90% of all interviews completed within one working day of the date the case was assigned to a county in the Colorado Electronic Disease Reporting System (CEDRS) or Dr. Justina when seven day incidence levels are between 0-100 cases per 100,000 population. 5. The Contractor shall consult with CDPHE if they are unable to meet the target for completing contact interviews. This target is 90% of all interviews completed within one working day of identification when seven day incidence levels are between 0-100 cases per 100,000 population. 6. The Contractor shall report cases meeting the probable and confirmed case definition into CEDRS or Dr. Justina or other CDPHE-designated system within one working day of 4 Contractor knowledge of the case. This case definition document is incorporated and made a part of this contract by reference and is available at the following website: https://docs.google.com/document/d/1e-IWLtzJNCgl2gzPO NGvEASGgse85WuBmcToc9ev-74/edit?usp=sharing 7. The Contractor shall utilize CEDRS, Dr. Justina or other CDPHE designated systems to report COVID-19 cases and contacts identified outside of their jurisdiction to CDPHE within one working day of identification. If the Contractor utilizes a different system for contact tracing, the Contractor shall report contacts identified outside of their jurisdiction to the appropriate local public health agency within one working day. 8. The Contractor shall utilize CEDRS or Dr. Justina or other CDPHE-designated system to record COVID-19 case and contact investigation data within one week of interview completion. If the Contractor utilizes a different system for contact tracing, the Contractor shall make contact investigation data available to CDPHE upon request. 9. CDPHE will run reports throughout the response to evaluate investigation timelines and data entry completion in CEDRS or Dr. Justina or other CDPHE designated systems. 10. The Contractor can select from the following COVID-19 epidemiological response activities for the plan; required activities are noted and 70% of the Contractor's budget (after indirect) must be allocated to required activities. Funded staff may work on other emerging infections and communicable diseases of public health significance if the COVID-19 workload decreases through the funding term. a. (required) Conduct case identification, investigation, management, and disease control strategy implementation (isolation). b. (required) Conduct contact identification, investigation, and disease control strategy implementation (quarantine). c. (required) Conduct outbreak reporting and investigation in non -state -run facilities. d. (required) Organize, administer, conduct, and/or maintain current knowledge of jurisdictional and community resources for COVID-19 testing. e. (required) Serve as an infection prevention liaison with CDPHE. 5 f. Conduct contact monitoring during quarantine to assess for symptoms and connect to testing. g. Conduct infection prevention activities, including participating with CDPHE infection prevention staff on infection control and response assessments, providing guidance to a variety of healthcare entities, assist in recruiting ambulatory (unregulated) health care settings to complete infection prevention assessment and training, and participating in infection prevention training. h. Provide case and contact support and resource connections through the isolation and quarantine periods, including but not limited to health, mental health, economic, and social support. Guidance around using these funds for quarantine and isolation support can be found at https://drive.google.com/file/d/1fw4jcupzBlH5O9S FPW3yo90x9ysFimEg/view. i. Conduct epidemiological data analysis for the jurisdiction. j. Conduct public and partner communication and education. k. Conduct community mitigation actions. 1. Conduct health equity activities around case investigation, contact tracing, testing, vaccination and other epidemiological response activities. m. Conduct vaccination activities. Vaccine -related activities must receive prior approval in writing from CDPHE. n. Conduct wastewater COVID-19 surveillance activities. o. Support COVID-19 administrative, leadership, legal, planning, and communication staffing and activities within the agency. 11. CDPHE will provide the funding acknowledgement letter within five (5) business days of contract execution. 12. The Contractor shall use the CDPHE budget template for the project budget. 13. CDPHE will provide the budget template within five (5) business days of contract execution. The budget can cover allowable expenses from January 14, 2021, through July 31, 2023. 6 14. CDPHE will send the quarterly online surveys to the Contractor to collect information about activities the Contractor is performing with this funding. The survey will include questions related to the following: a. Epidemiological activities b. Testing activities c. Health equity activities d. Infection prevention activities (including identifying the infection prevention liaison at the LPHA) e. Budget updates 15. The statewide CDPHE/local public health agency COVID-19 webinars are held on Tuesdays and Thursdays from 12:30 PM - 1:30 PM, and recordings are available for one week after the call in the COVID-19 LPHA Google folder (https: //drive.google.com /drive/folders/19rIh3Vy6BXF-17S OQilTCwHDVsZmG f0). Call frequency may be adjusted as the pandemic progresses, and will be communicated via email. CDPHE will monitor call attendance by downloading participant lists from the webinar service and monitor viewing of meeting recording. 16. The Contractor shall use the CDPHE testing plan template to provide jurisdictional testing information to CDPHE. CDPHE intends to support testing activities through the duration of the project period. Jurisdictional testing information can include CDPHE-supported mechanisms and other mechanisms. 17. The Contractor shall use the "COVID-19 outbreak report form" found in this Google folder for initial and final outbreak reports: https://drive.google.com/drive/folders/1JyhL mUgP-RFJi9 TllvX0eZo8pVg-zju. Additional outbreak resources and tools can be found in this folder. 18. The Contractor shall reference the Google Map of CDPHE COVID-19 Epi Teams to determine the team assigned to the Contractor's jurisdiction. Outbreak initial reports, line lists, and final reports shall be submitted to the appropriate team email address; alternatively, outbreak initial reports and final reports can be emailed to the outbreak email inbox: cdphe_covid_outbreak®state.co.us. This Google Map is incorporated and made a part of this contract by reference and is available at the following website: https://www.google.com /maps/d/u/0/viewer?ll=39.681381 7 699999996%2C-104.8544189btz=8amid=1 vySlE7ORfgCb7FPn2 D89xC-2CXfbAbTw 19. The Contractor shall utilize CDPHE infection prevention guidance if support is provided to Residential Care Facilities within their jurisdiction. The Contractor shall not impose limitations that are more restrictive than CDPHE guidance. CDPHE guidance can be found at: https: / /covidl 9.colorado.gov/ltcf. 20. CDPHE will provide ventilation guidance and toolkit information to the Contractor. 21. The Contractor shall participate in CDPHE led post award meeting(s). 22. The Contractor shall ensure all funding requirements are met with all expenses including subcontractors. 23. The Contractor shall ensure project budget is paced throughout the full term of the contract. Vaccine -related activities must receive prior approval in writing from CDPHE. 24. The Contractor shall communicate any projected budget changes to the CDPHE contract monitor that may result in unobligated funds within 30 days of acknowledgment of changes or by the designated deliverables within 6 months and 12 months of contract expiration. Projected budget changes could be staff changes, changes in county support, lack of COVID-19 work, etc. 25. The Contractor shall respond to identified performance improvements and needs that may arise in activities, reporting, deliverables, and budget pacing. 26. The Contractor shall respond to CDPHE inquiries on health equity activities and quarterly report submissions. 27. The Contractor shall continue to meet deliverables contained in the ELC Enhancing Detection funding statement of work that was provided in June 2020. 8 Expected Results of Activity(s) 1. Activities will contribute to the containment of COVID-19. 2. The Contractor will provide high quality public health surveillance and epidemiological investigation of COVID-19 cases, contacts, and outbreaks in line with state and federal requirements and best practices. 3. The Contractor shall maintain satisfactory performance outlined in the statement of work. Measurement of Expected Results 1. CDPHE will tabulate data in CEDRS and Dr. Justina, or other CDPHE-designated systems, on a regular basis to track the containment of COVID-19. 2. CDPHE will calculate monthly investigation metrics to measure and track the quality of investigations of COVID-19 cases, contacts, and outbreaks. 3. CDPHE will evaluate Contractor performance on a quarterly basis at minimum. Completion Date Deliverables 1. The Contractor shall submit a plan, using the CDPHE template, identifying the COVID-19 epidemiological activities that require personnel funding and capacity plan for case investigation, contact tracing, and outbreak investigation via email to the CDPHE Contract Monitor. No later than 45 days after the execution of the contract 2. The Contractor shall submit a project budget via email to the CDPHE Contract Monitor. No later than 45 days after execution of the contract 3. The Contractor shall submit the budget revision via email to the CDPHE Contract Monitor. No later than 30 days after the last day of Quarter 3, annually 9 4. The Contractor shall notify the CDPHE Contract Monitor via email of unobligated funds. No later than July 21, 2022 and by January 31, 2023 5. The Contractor shall respond to a survey to report progress via email from CDPHE. Quarterly, by the last day of the month starting in July 2021 6. The Contractor shall submit a COVID-19 testing plan for the jurisdiction via email to the CDPHE Contract Monitor. No later than August 2, 2021 7. The Contractor shall submit line lists for all active outbreaks in their jurisdiction weekly by noon on Tuesday via email to the CDPHE Team listed on the Google Map of CDPHE COVID-19 Epi Teams. Weekly through July 31, 2023 8. The Contractor shall report COVID-19 outbreaks to the respective CDPHE COVID-19 Epi Team or outbreak email inbox. Within 24 hours of identifying the outbreak 9. The Contractor shall submit final outbreak report forms to the appropriate CDPHE COVID-19 Epi Team or outbreak email inbox. Within 2 weeks of the outbreak meeting closure criteria 10. The Contractor shall submit their reimbursement for expenses from January 14, 2021 through April 30, 2021, for reimbursement to the CDPHE Contract Monitor. No later than 45 days after execution of the contract. 10 11. The Contractor shall submit the No later than 30 days list of residential care facilities before the end of the where ventilation guidance and contract. the toolkit were provided via email to the CDPHE Contract Monitor. 12. The Contractor shall submit a No later than 45 days signed funding acknowledgement after execution of the letter, using the CDPHE provided contract template. IV. ADDITIONAL PROVISIONS - Payment Structure To receive compensation under the Purchase Order, the Contractor shall submit a signed Monthly Invoice Form. This ELC Simplified Invoice template is accessible from the CDPHE COVID-19 Fiscal website located at this link: https://docs.Qoogle.com/spreadsheets/d/1URSoUoGmzAv6 0QPJx-b74BXw7R0gEbezkL-RivOXI w/edit#Rid=121834738; the form is incorporated and made part of this statement of work by reference. The Invoice Form must be submitted no later than forty-five (45) calendar days after the end of the billing period for which services were rendered. Expenditures shall be in accordance with the Statement of Work and Budget. Scan the completed and signed Invoice Form and supporting documentation into an electronic document. Email the Invoice form and general ledger supporting documentation to your regional contract monitor. Supporting documentation must be maintained and may be requested to verify compliance is met with funding requirements. Unless otherwise provided for in the Purchase Order, "Local Match", if any, shall be included on all invoices as required by the funding source. The Contractor shall not use federal funds to satisfy federal cost sharing and matching requirements unless approved in writing by the appropriate federal agency. Final billings under the Purchase Order must be received by the State within a reasonable time after the expiration or termination of the Purchase Order; but in any event no later than forty-five (45) calendar days from the effective expiration or termination date of the Purchase Order. 11 To ensure funding is available to complete deliverables throughout the period of performance, the Contractor shall not invoice for more than the percent available as follows: Period Percent available for invoicing Through 6/30/21 30% Through 12/31/21 50% Through 6/30/22 85% Through 12/31/22 95% Through 7/31/23 100% V. Monitoring: CDPHE's monitoring of this contract for compliance with performance requirements will be conducted throughout the contract period by the Contract Monitor. Methods used will include a review of documentation determined by CDPHE to be reflective of performance to include progress reports and other fiscal and programmatic documentation as applicable. VI. Resolution of Non -Compliance: The Contractor will be notified in writing within (10) calendar days of discovery of a compliance issue. Within (5) calendar days of discovery, the Contractor and the State will collaborate, when appropriate, to determine the action(s) necessary to rectify the compliance issue and determine when the action(s) must be completed. The action(s) and timeline for completion will be documented in writing and agreed to by both parties. If extenuating circumstances arise that require an extension to the timeline, the Contractor must email a request to the Contract Monitor and receive approval for a new due date. The State will oversee the completion/implementation of the action(s) to ensure timelines are met and the issue(s) is resolved. If the Contractor demonstrates inaction or disregard for the agreed upon compliance resolution plan, the State may exercise its rights under the provisions of this contract. CDPHE monitoring findings of non-performance, inadequate performance, or excessive unobligated funds without an adequate spenddown plan may result in a revision to this Statement of Work and a reduction or termination of ELC COVID funding. 12 COLORADO Enhancing Detection (ELC) Round 2 Expense Allowability Roadmap Department of Public Health & Environment May 17, 2021 ELC COVID-19 containment funding priorities include: case investigation/contact tracing (Cl/CT), outbreak investigation, testing, and funding to support our local partners. Due to the nature and speed of the agreements, it is extremely important to provide guidance that summarizes federal and state legal requirements on allowable costs. In addition to meeting the allowability requirements, all expenses must be allocable to the scope of work, be reasonable, and consistent with documented agency policy. PRIOR APPROVAL IS REQUIRED FOR VACCINE EFFORTS USING ELC FUNDS AND ACCELERATED SPENDING. This document summarizes the allowable and unallowable costs in the PQ (5/10/21 - 7/30/23) 5OW. ELC Round 2 Funding Granted Expense Category Allowable Unallowable Personnel Salaries, fringe and benefits, time and overtime substantially dedicated to COVID-19 SOW activities. Includes permanent, term -limited, temporary, contracted staff or students. Research, lobbying, clinical care, overtime expenses for law enforcement, vaccine administration, reimbursement of pre -award costs. Equipment General and special purpose equipment (laboratory equipment, generators, freezers, refrigerators), vaccine storage equipment with prior approval. Telecommunications equipment produced by Huawei Technologies or ZTE Corp, Hytera Communications, Hangzhou Hikvision Digital Technology, or Dahua Technology, etc.' Supplies Testing supplies, PPE for staff responding (for vaccine staff requires prior approval), telephone and communication, office, postage, computers, radios, cell phones, etc. Meals, snacks, alcoholic beverages, gift cards, CSTE conference registration, advertising (conventions, memorabilia, souvenirs), entertainment, vaccine. Software Software/systems for COVID-related lab or Cl/CT data analysis, GIS, tools for rapid notification, services for cloud or video conference, etc. Software associated with vaccine registries or tracking of vaccine. Vehicle Leasing vehicles such as mobile testing units, or vehicles that provide public health services in underserved areas with prior approval. Vehicle purchases. Quarantine / Isolation (Q/I) Lodging, food, laundry, mental health services, etc. -- see guidance. N/A Outreach / Education Communication materials, health education to support Q/I, health education to support Cl/CT. Expenses used to influence legislation, appropriations, regulation, administrative action, or executive orders proposed to a legislative body. Stipends / Incentives N/A Not allowed. Contractors Support SOW activities through Cl/CT, private labs, healthcare entities, testing support, Q/I, wastewater surveillance, etc. Subcontractors require approval. N/A Travel In state travel, mileage, rentals, fleet fuel, lodging, per diem. Meals, snacks, alcoholic beverages, gift cards, CSTE conference registration, advertising (conventions, displays, memorabilia, souvenirs, gifts), and entertainment. Indirect Allowed based on approved rate. N/A 'Telecommunications/video surveillance equipment by SD consultation with the NI or FBI director reasonably believes to be an entity owned or controlled by, or otherwise, connected to the government of a covered foreign country. COVID-19 Epi Team Contacts I COVID-19 Contract Monitor Contacts I Fiscal WEBSITE Federal Provisions — Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) For the purposes of this Exhibit only, Contractor is also identified as "Subrecipient." This Contract has been funded, in whole or in part, with an award of Federal funds. In the event of a conflict between the provisions of these Supplemental Provisions for Federal Awards, the Special Provisions, the Contract or any attachments or exhibits incorporated into and made a part of the Contract, the Supplemental Provisions for Federal Awards shall control. In the event of a conflict between the Supplemental Provisions for Federal Awards and the FFATA Supplemental Provisions (if any), the FFATA Supplemental Provisions shall control. 1) Federal Award Identification. a. Subrecipient: Weld County Dept of Public Health & Env. b. Subrecipient DUNS number: 75757955 c. The Federal Award Identification Number (FAIN) is NU50CK000552. d. The Federal award date is 1/4/21. e. The subaward period of performance start date is 5/10/2021 and end date is 7/31/2023. f Federal Funds: Federal Budget Period Total Amount of Federal Funds Awarded Amount of Federal Funds Obligated to CDPHE 8/1/2020 - 7/31/2021 $ 5,937,731.00 $331,463,532.00 g. Federal award title of project or program: Epidemiology and Laboratory Capacity for Infectious Diseases (ELC). h. The name of the Federal awarding agency is: Department of Health and Human Services Centers for Disease Control and Prevention and the contact information for the awarding official is Ms. Joelle Cadet Grants Management Specialist qrx2@cdc.gov (404)498-4349; the name of the pass -through entity is the State of Colorado, Department of Public Health and Environment (CDPHE), and the contact information for the CDPHE official is Ms. Nicole Comstock nocole.comstock@state.co.us (303)692-2676. i. The Catalog of Federal Domestic Assistance (CFDA) number is 93.323 and the grant name is Epidemiology and Laboratory Capacity for Infectious Diseases (ELC). j. This award is not for research & development. k. Subrecipient is not required to provide matching funds. In the event the Subrecipient is required to provide matching funds, Section 8 of this Attachment applies. 1. The indirect cost rate for the Federal award (including if the de minimis rate is charged per 2 CFR §200.414 Indirect (F&A) costs) is pre -determined based upon the State of Colorado and CDPHE cost allocation plan. 2) Subrecipient shall at all times during the term of this contract strictly adhere to the requirements under the Federal Award listed above, and all applicable federal laws, Executive Orders, and implementing regulations as they currently exist and may hereafter be amended. Page 1 of 5 Ver. 23.03.20 3) Any additional requirements that CDPHE imposes on Subrecipient in order for CDPHE to meet its own responsibility to the Federal awarding agency, including identification of any required financial and performance reports, are stated in the Exhibits. 4) Subrecipient's approved indirect cost rate is as stated in the Exhibits. 5) Subrecipient must permit CDPHE and auditors to have access to Subrecipient's records and fmancial statements as necessary for CDPHE to meet the requirements of 2 CFR §200.331 Requirements for pass -through entities, §§ 200.300 Statutory and National Policy Requirements through §200.309 Period of performance, and Subpart F —Audit Requirements of this Part. 6) The appropriate terms and conditions concerning closeout of the subaward are listed in Section 16 of this Attachment. 7) Performance and Final Status. Subrecipient shall submit all financial, performance, and other reports to CDPHE no later than 45 calendar days after the period of performance end date or sooner termination of this Contract containing an evaluation and review of Subrecipient's performance and the final status of Subrecipient's obligations hereunder. 8) Matching Funds. Subrecipient shall provide matching funds as stated in the Exhibits. Subrecipient shall have raised the full amount of matching funds prior to the Effective Date and shall report to CDPHE regarding the status of such funds upon request. Subrecipient's obligation to pay all or any part of any matching funds, whether direct or contingent, only extends to funds duly and lawfully appropriated for the purposes of this Contract by the authorized representatives of the Subrecipient and paid into the Subrecipient's treasury or bank account. Subrecipient represents to CDPHE that the amount designated as matching funds has been legally appropriated for the purposes of this Contract by its authorized representatives and paid into its treasury or bank account. Subrecipient does not by this Contract irrevocably pledge present cash reserves for payments in future fiscal years, and this Contract is not intended to create a multiple -fiscal year debt of the Subrecipient. Subrecipient shall not pay or be liable for any claimed interest, late charges, fees, taxes or penalties of any nature, except as required by Subrecipient's laws or policies. 9) Record Retention Period. The record retention period previously stated in this Contract is replaced with the record retention period prescribed in 2 CFR §200.333. 10) Single Audit Requirements. If Subrecipient expends $750,000 or more in Federal Awards during Subrecipient's fiscal year, Subrecipient shall procure or arrange for a single or program -specific audit conducted for that year in accordance with the provisions of Subpart F -Audit Requirements of the Uniform Guidance, issued pursuant to the Single Audit Act Amendments of 1996, (31 U.S.C. 7501-7507). 2 CFR §200.501. 11) Contract Provisions. Subrecipient shall comply with and shall include all of the following applicable provisions in all subcontracts entered into by it pursuant to this Contract: a. Office of Management and Budget Circulars and The Common Rule for Uniform Administrative Requirements for Grants and Cooperative Agreements to State and Local Governments, as applicable; b. when required by Federal program legislation, the "Davis -Bacon Act", as amended (40 U.S.C. 3141-3148) as supplemented by Department of Labor Regulations (29 CFR Part 5, "Labor Standards Provisions Applicable to Contracts Covering Federally Financed and Assisted Construction"); c. when required by Federal program legislation, the Copeland "Anti -Kickback" Act (40 U.S.C. 3145), as supplemented by Department of Labor regulations (29 CFR Part 3, "Contractors and Subcontractors on Public Building of Public Work Financed in Whole or in Part by Loans or Grants from the United States"). Page 1 of 5 Ver. 23.03.20 d. 42 U.S.C. 6101 g( sera 42 U.S.C. 2000d, 29 U.S.C. 794 (regarding discrimination); e. the "Americans with Disabilities Act" (Public Law 101-336; 42 U.S.C. 12101, 12102, 12111 - 12117, 12131 - 12134, 12141 - 12150, 12161 - 12165, 12181 - 12189, 12201 - 12213 and 47 U.S.C. 225 and 47 U.S.C. 611); f. when applicable, the Contractor shall comply with the provisions of the "Uniform Administrative Requirements for Grants and Cooperative Agreements to State and Local Governments" (Common Rule); g. The Federal Funding Accountability and Transparency Act of 2006 (Public Law 109-282), as amended by §6062 of Public Law 110-252, including without limitation all data reporting requirements required there under. This Act is also referred to as FFATA. h. Contractor shall comply with the provisions of Section 601 of Title VI of the Civil Rights Act of 1964, as amended. i. Except as otherwise provided under 41 CFR Part 60, all contracts that meet the definition of "federally assisted construction contract" in 41 CFR Part 60-1.3 comply with the equal opportunity clause provided under 41 CFR 60-1.4(b), in accordance with Executive Order 11246, "Equal Employment Opportunity: (30 FR 12319, 12935, 3 CFR Part, 1964-1965 Comp., p. 339), as amended by Executive Order 11375, "Amending Executive Order 11246 Relating to Equal Employment Opportunity," and implementing regulations at 41 CFR part 60, "Office of Federal Contract Compliance Programs, Equal Employment Opportunity, Department of Labor. j. where applicable, Contract Work Hours and Safety Standards Act (40 U.S.C. 3701-3708). k. if the Federal award meets the definition of "funding agreement" under 37 CFR § 401.2 (a) and the recipient or subrecipient wishes to enter into an agreement with a small business firm or nonprofit organization, comply with the requirements of 37 CFR Part 401, "Rights to Inventions Made by Nonprofit Organizations and Small Business Firms Under Government Grants, Contracts and Cooperative Agreements," and any implementing regulations issued by the awarding agency. 1. the Clean Air Act (42 U.S.C. 7401-7671q.) and the Federal Water Pollution Control Act (33 U.S.C. 1251-1387), as amended. m. if applicable, comply with the mandatory standards and policies on energy efficiency contained within the State of Colorado's energy conservation plan issued in compliance with the Energy Policy and Conservation Act, 42 U.S.C. 6201. n. the Contractor and all principals are not presently debarred, suspended, proposed for debarment, declared ineligible, or voluntarily excluded from covered transactions by any federal department or agency; the Contractor and all principals shall comply with all applicable regulations pursuant to Executive Order 12549 (3 CFR Part 1986 Comp., p. 189) and Executive Order 12689 (3 CFR Part 1989 Comp., p. 235), Debarment and Suspension; and, o. the Contractor shall comply where applicable, the Byrd Anti -Lobbying Amendment (31 U.S.C. 1352). 12) Compliance. Subrecipient shall comply with all applicable provisions of The Office of Management and Budget Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance), including but not limited to these Supplemental Provisions for Federal Awards. Any revisions to such provisions automatically shall become a part of these Supplemental Provisions, without the necessity of either party executing any further instrument. CDPHE may provide Page 1 of 5 Ver. 23.03.20 written notification to Subrecipient of such revisions, but such notice shall not be a condition precedent to the effectiveness of such revisions. 13) Procurement Procedures. Subrecipient shall use its own documented procurement procedures which reflect applicable State, local, and Tribal laws and regulations, provided that the procurements conform to applicable Federal law and the standards identified in the Uniform Guidance, including without limitation, §§200.318 through 200.326 thereof 14) Certifications. Unless prohibited by Federal statutes or regulations, CDPHE may require Subrecipient to submit certifications and representations required by Federal statutes or regulations on an annual basis (2 CFR §200.208). Submission may be required more frequently if Subrecipient fails to meet a requirement of the Federal award. Subrecipient shall certify in writing to CDPHE at the end of the Contract that the project or activity was completed or the level of effort was expended. 2 CFR §200.201(b)(3). If the required level of activity or effort was not carried out, the amount of the Contract must be adjusted. 15) Event of Default. Failure to comply with the Uniform Guidance or these Supplemental Provisions for Federal Awards shall constitute an event of default under the Contract pursuant to 2 CFR §200.339 and CDPHE may terminate the Contract in accordance with the provisions in the Contract. 16) Close- Out. Subrecipient shall close out this Contract within 45 days after the End Date. Contract close out entails submission to CDPHE by Subrecipient of all documentation defined as a deliverable in this Contract, and Subrecipient's final reimbursement request. If the project has not been closed by the Federal awarding agency within 1 year and 45 days after the End Date due to Subrecipient's failure to submit required documentation that CDPHE has requested from Subrecipient, then Subrecipient may be prohibited from applying for new Federal awards through the State until such documentation has been submitted and accepted. 17) Erroneous Payments. The closeout of a Federal award does not affect the right of the Federal awarding agency or CDPHE to disallow costs and recover funds on the basis of a later audit or other review. Any cost disallowance recovery is to be made within the record retention period. EXHIBIT END Page 1 of 5 Ver. 23.03.20 r Congressional Research Service Informing the legislative debate since 1914 Consolidated Appropriations Act, 2021 (P.L. 116-260): Emergency Capital Investment Program January 5, 2021 The Coronavirus Disease 2019 (COVID-19) pandemic has had devastating economic effects, including a significant increase in unemployment. Certain studies indicate that low- and moderate -income communities and minorities have borne this economic hardship to a disproportionately high degree, such as by being more likely to experience job loss and difficulty paying for necessities. Division N, Title V, Section 522, of Consolidated Appropriations Act, 2021 (P.L. 116-260), establishes the Emergency Capital Investment Program (ECIP) through which the Treasury Department can make capital investments in certain depositories (i.e., banks, savings associations, and credit unions). The purpose of the program is to increase the availability of credit, grants, and forbearances to groups disproportionately affected by the pandemic. The program shares certain similarities with previous Treasury capital investment programs. Emergency Capital Investment Program Section 522 allows Treasury to make investments in eligible institutions to support their efforts to "provide loans, grants, and forbearance for small businesses, minority -owned businesses, and consumers, especially in low-income and underserved communities ... that may be disproportionately impacted by the economic effects of the COVID-19 pandemic." Total investments cannot exceed $9 billion; $4 billion is set aside for institutions with less than $2 billion in assets, of which $2 billion is set aside for institutions with less than $500 million. Eligible institutions include depositories that are either (1) minority depository institutions (i.e., 51% or more owned by individuals who are minorities) or (2) a Community Development Financial Institution (CDFI). CDFIs are entities, some of which are not depositories, certified to receive grants and other assistance from the CDFI Fund established by the Riegle Community Development and Regulatory Improvement Act of 1994 (P.L. 103-325) because their business plans include a focus on fostering economic development in target neighborhoods or groups. Under ECIP, eligible institutions must submit applications to participate, including information about how the investments will be used meet the needs of communities disproportionately affected by the pandemic. The Treasury will purchase capital (e.g., preferred stock or a similar financial instrument) issued by CRS INSIGHT Prepared for Members and Committees of Congress _ Congressional Research Service https://crsreports.congress.gov IN11565 Congressional Research Service 2 approved institutions. If an institution does not repay the investment by the end of a 10 -year period, the Treasury can reset the terms. No dividend will be due within the first two years of the stock issuance. Then, the dividend rate will be based on how much the institution's lending to certain groups has grown relative to the size of the investment in a way that provides incentives for lending to those groups. Institutions that have increased lending to minority, rural, and urban low-income and underserved communities and to low- and moderate -income borrowers by more than 400% of the investment amount will pay a 0.5% annual rate. Institutions with lending growth to those groups of between 200% and 400% of the investment will pay 1.25%. Institutions that do not achieve those growth rates will pay 2%. The most Treasury can invest in one bank is limited to $250 million, and the size of the capital investment is limited to a percentage of a bank total assets, ranging from 7.5% of total assets for institutions with more than $2 billion in assets to 22.5% for institutions with less than $500 million. The Treasury has discretion to set terms and conditions and implement regulations to ensure that program goals are met, provide incentives for repayment, protect against conflicts of interest, and protect the interest of the federal government, among other goals. The Treasury faces certain restrictions on the sale of the instruments to third parties. The authority to make investments under the ECIP expires six months after the termination date for the national emergency declared by the President on March 13, 2020, under the National Emergencies Act (P.L. 94-412). Previous Capital Investment Programs Troubled Asset Relief Program Though the cause of the economic contractions are different, the magnitude of the current recession draws comparisons to the recession caused by the 2007-2009 financial crisis. That crisis and its economic fallout elicited major government interventions, including programs in which the Treasury made capital investments in banks. The Treasury established the Troubled Asset Relief Program (see CRS Report R41427, Troubled Asset Relief Program (TARP): Implementation and Status) pursuant to the Emergency Economic Stabilization Act of 2008 (EL. 110-343), which included five bank investment programs. One program, the Capital Purchase Program (CPP), made nearly $205 billion of investments in 707 financial institutions that were deemed "viable" —that is, solvent and not in immediate danger of failing —with the goal of bolstering their capital positions, boosting confidence in the banking system, and supporting lending to consumers and businesses. Another program, the Community Development Capital Initiative (CDCI), made capital investments in viable depositories that were CDFIs on more favorable terms than those of the CPP. The CDCI made $570 million of investments in 84 institutions. As of December 2020, the Treasury had received repayments, dividends, and sales worth $226 billion from CPP investments and $590 million from CDCI investments. Small Business Lending Fund To support employment and small businesses after the 2007-2009 recession, Congress passed the Small Business Jobs Act of 2010 (SBJA; P.L. 111-240). Section 4103 of the SBJA established another capital investment program called the Small Business Lending Fund (SBLF; see CRS Report R42045, The Small Business Lending Fund). The act authorized the Treasury to invest up to $30 billion through the SBLF in small banks and Community Development Loan Funds (CDLFs), a type of nondepository CDFI. Congressional Research Service 3 Ultimately, the Treasury invested over $4.0 billion in 332 institutions: $3.9 billion in 281 community banks and $104 million in 51 CDLFs. The SBJA required that participating banks pay a 5% dividend for the first two years of SBLF investment and reduced that dividend in subsequent years if the bank had increased its small business lending by certain amounts. For example, if the bank increased its business lending by 2.5% to 5%, it would pay a 4% dividend. The dividend could be set as low as 1% if the increase in small business lending was greater than 10%. This feature of setting a dividend rate based on how much a bank lent to a particular market segment is similar to the dividend feature in the ECIP. Author Information David W. Perkins Specialist in Macroeconomic Policy Disclaimer This document was prepared by the Congressional Research Service (CRS). CRS serves as nonpartisan shared staff to congressional committees and Members of Congress. It operates solely at the behest of and under the direction of Congress. Information in a CRS Report should not be relied upon for purposes other than public understanding of information that has been provided by CRS to Members of Congress in connection with CRS's institutional role. CRS Reports, as a work of the United States Government, are not subject to copyright protection in the United States. Any CRS Report may be reproduced and distributed in its entirety without permission from CRS. However, as a CRS Report may include copyrighted images or material from a third party, you may need to obtain the permission of the copyright holder if you wish to copy or otherwise use copyrighted material. IN11565 VERSION 2 • NEW ELC ENHANCING DETECTION THROUGH CORONAVIRUS RESPONSE AND RELIEF (CRR) SUPPLEMENTAL FUNDS - DRAFT 1/7/2021 Project E: Emerging Issues Funding for the Enhanced Detection, Response, Surveillance, and Prevention of COVID-19 Supported through the Coronavirus Response and Relief Supplemental Appropriations Act of 2021 ELC Enhancing Detection Expansion Guidance - 1/12/2021 CONTENTS Background and purpose 1 2 3 4 5 5 6 Required Tasks 8 Activities 9 Performance measures and reporting 16 Acknowledgement Letter: Due within five (5) days of NOA Receipt 17 Jurisdictional Testing, Case Investigation, and Contact Tracing Plans Funding strategy Allowable Costs Support to Local Health Departments (LHD) Supporting Management of Activities and Resources Process for workplan and budget submission ELC ENHANCING DETECTION EXPANSION PROJECT E: EMERGING ISSUES BACKGROUND AND PURPOSE *Note: As the 'ELC Enhancing Detection Expansion' guidance is intended to build upon the prior work supported under 'ELC Enhancing Detection', this guidance contains the language from the 'ELC Enhancing Detection' guidance. In instances where sections and activities have been expanded, the language will appear in red font; whereas, language left unaltered will remain in black font. This guidance is intended to provide details regarding $19.11 billion from the Coronavirus Response and Relief Supplemental Appropriations Act of 2021, P.L. 116-260, that will be provided to ELC recipients early in 2021. While the activities largely build upon those under Enhancing Detection, specific details of the guidance should be reviewed in total for important context and clarification. As part of the CARES Act and Paycheck Protection Program and Health Care Enhancement Act supplements, the ELC awarded approximately $11 billion in 2020 to help address the domestic response to COVID-19. To provide additional critical support to jurisdictions as they continue to address COVID-19 within their communities, $19.11 billion from the Coronavirus Response and Relief Supplemental Appropriations Act of 2021, P.L. 116-260, will be provided to ELC recipients. These additional resources, by law, are intended to "prevent, prepare for, and respond to coronavirus" by supporting testing, case investigation and contact tracing, surveillance, containment, and mitigation. Such activities may include support for workforce, epidemiology, use by employers, elementary and secondary schools, child care facilities, institutions of higher education, long-term care facilities, or in other settings, scale up of testing by public health, academic, commercial, and hospital laboratories, and community -based testing sites, mobile testing units, health care facilities, and other entities engaged in COVID-19 testing, and other activities related to COVID-19 testing, case Wage ELC Enhancing Detection Expansion Guidance - 1/12/2021 investigation and contact tracing, surveillance, containment, and mitigation (including interstate compacts or other mutual aid agreements for such purposes). As with the previous awards, direct recipients are limited to existing jurisdictions covered under CK19-19041. Recipients should continue to build upon existing ELC infrastructure that emphasizes the coordination and critical integration of laboratory with epidemiology and health information systems in order to maximize the public health impact of available resources. It is the role of the recipient's ELC Project Director to ensure funds are used to achieve the required activities in this guidance; and to guarantee these new funds do not duplicate financial support through prior awards. These funds are intended to complement and not duplicate resources from any other federal source, including those previously awarded via the ELC Cooperative Agreement. Similarly, these resources are not intended to be applied without foresight, consideration for, and planning to address future infectious disease events. Ongoing monitoring of milestones and performance measures will be utilized to gauge progress toward successful completion of priority activities supported with these funds. Recipients will again be required to complete and submit Jurisdictional Testing, Case Investigation, and Contact Tracing Plans (please note that these may be published on the HHS website: https://www.hhs.gov/coronavirus/testing-plans/index.html). The following guidance outlines other specific details and requirements accompanying the resources. JURISDICTIONAL TESTING, CASE INVESTIGATION, AND CONTACT TRACING PLANS Utilizing the provided template, located in REDCap, recipients will update information regarding the overall testing landscape within their jurisdiction. This exercise should be done in partnership with state/jurisdictional leadership (e.g., public health, emergency management, State Health Official, local health departments, etc.) and should reflect the approach to testing at a broad jurisdictional level, including tribal needs as appropriate. For example, testing done at public health, clinical and/or commercial labs should be included as well as approaches for reaching communities placed at greater risk for COVID-19, and the application and use of various types of testing for detection and/or surveillance (antigen, molecular, and serology) and inform contact investigation and tracing efforts. These plans should include aspects of advanced molecular detection (AMD) technologies to inform and drive investigations utilizing molecular epidemiology techniques. Jurisdictions must provide details regarding their robust SARS-CoV-2 testing, case investigation, and contact tracing program that ensures adequate testing is made available according to CDC priorities, including but not limited to: diagnostic tests, tests for close contacts of cases, and expanded screening testing for asymptomatic persons to identify and isolate infectious individuals and monitor community spread. Recipients should assure that provisions are in place to meet future surge capacity testing needs including point -of -care or other rapid testing for outbreaks. Plans should include provisions for testing at, and reporting from, non-traditional sites (e.g., schools, retail sites, community centers, residential medical facilities, or pharmacies); testing of populations at higher risk of becoming infected with SARS-CoV-2 due to high frequency of residential, occupational or nonoccupational contacts; and should also address any essential partnerships with academic, commercial, and hospital laboratories to successfully meet testing demand. In conjunction with optimizing testing and increasing test volumes for COVID-19/SARS-CoV-2, resources will support the establishment of modernized, timely (real-time) public health surveillance (e.g., to help support case investigation and contact tracing) and health information systems. These systems will support the public health response to COVID-19 and 1 Only current ELC recipients are eligible to receive awards associated with the supplement described in this guidance. While tribal nations are not included in these awards, other federal support is provided in the Coronavirus Response and Relief Supplemental Appropriations Act of 2021. Wage ELC Enhancing Detection Expansion Guidance - 1/12/2021 lay the foundation for the future of public health surveillance. Establishing systems and processes to report the data categories described in this document on a daily, automated basis to state and federal health systems is a requirement of accepting these funds, if such systems are not already in place. These systems must be transparent and visible to communities through an open website. For each data category, data elements will be specified by CDC for each reportable condition (e.g., race/ethnicity) at a later date. Both existing and newly established surveillance and data reporting systems must: 1. Ensure that real-time, at least daily, complete and accurate test orders and results can be exchanged within the healthcare/public health system and simultaneously reported to CDC and others via automated systems in a machine-readable format. These systems must support reporting of test results at the county or zip code level with additional data fields as specified by CDC [e.g., Ask on Entry (AOE) questions]. This includes not only testing for the presence of virus (nucleic acid or antigen testing), but also serological testing documenting past infection. 2. Ensure real-time, at least daily, complete, automated reporting in a machine-readable format for the following data categories: case, hospitalization and death reporting; emergency department syndromic surveillance; and capacity, resources, and patient impact at healthcare facilities through electronic reporting. 3. Support the display of up-to-date, critical public health information relating to COVID-19 and future outbreaks at the county or zip code level in visual dashboards or tables on county or state websites, including case data and syndromic surveillance data. Enhancements to epidemiologic activities resulting from additional test data are also fundamental to controlling the spread of COVID-19. Recipients must accelerate efforts to conduct robust case investigation and contact tracing and then identify and isolate new cases of COVID-19 among symptomatic or asymptomatic individuals. This information should be further utilized to understand COVID-19/SARS-CoV-2 transmission within a community and determine appropriate mitigation strategies. FUNDING STRATEGY Funding by jurisdiction will be based on population, as provided in the legislative language for the Coronavirus Response and Relief Supplemental Appropriations Act of 2021 (https://rules.house.gov/sites/democrats. rules.house.gov/files/BILLS-116HR133SA-RCP-116-68.pdf). Direct Assistance is authorized under CK19-19042; however, should opportunities for direct assistance be made available, these will be shared broadly with our recipient base and options for providing direct assistance in lieu of financial assistance may be discussed and coordinated with the ELC Project Officer and the CDC Office of Grant Services (OGS). 'Legislative Authority for CK19-1904: Sections 301 and 317 of the Public Health Service Act (PHS Act), 42 USC sections 241 and 247b, as amended; and funding is, in part, appropriated under Affordable Care Act (PL 111-148), Title IV, Section 4002 (Prevention and Public Health Fund), Title IV, Section 4002. 3IPage ELC Enhancing Detection Expansion Guidance - 1/12/2021 ALLOWABLE COSTS Recipients should consider requesting the following when developing budgets, in furtherance of award activities. The financial resources provided are required, by law, to support activities intended to address prevention and response to COVID-19. 1. Personnel (term, temporary, students, overtime, contract staff, etc.). 2. Laboratory equipment and necessary maintenance contracts. 3. Collection supplies, test kits, reagents, consumables and other necessary supplies for existing testing or onboarding new platforms. 4. Courier service contracts (new or expansion of existing agreements). 5. Hardware and software necessary for robust implementation of electronic laboratory and surveillance data exchange between recipient and other entities, including healthcare entities, jurisdictional public health and CDC. 6. Tools that assist in the rapid identification, electronic reporting, monitoring, analysis, and evaluation of control measures to reduce the spread of disease (e.g. GIS software, visualization dashboards, cloud services). 7. Contracts with academic institutions, private laboratories, other non-commercial healthcare entities, and/or commercial entities. 8. Renovations and minor construction (e.g., alteration of less than 50% total square footage of an existing structure; installation of a concrete slab for modular laboratory units; etc.) may be considered for unique cases where conditions do not currently allow for safe or effective testing and/or delivery of effective public health services. 9. Leasing/purchasing vehicles (e.g., mobile testing, providing public health services in underserved areas, etc.). Note: Recipients will need to submit quotes with their revised budgets that are due within 60 days of award issuance and receive prior approval from OGS. After the revised NOA is issued, any further request for leasing/purchasing must be made through GrantSolutions and include the necessary quotes. 10. Software or systems to assist with laboratory resource management (e.g., software for inventory management, temperature notifications, etc.), quality management, biosafety or training needs. 11. Quarantine and isolation support necessary for preventing the spread of COVID-19 (including wraparound services such as hoteling, food, laundry, mental health services, etc.). 12. Stipends/incentives may be considered to encourage participation in testing and/or vaccination coverage for those put at higher risk for COVID-19 (individual level) or for facilities/agencies to enroll and/or report data to the health department (institutional level). Recipients interested in exploring this option (individual and/or institutional) must submit a plan that covers all of the following elements: (a) justification, (b) cost savings [e.g., how it will defray costs or have a positive return on investment], (c) defined amount, (d) qualifications for issuance, and (e) method of tracking. When submitting the revised budget within 60 days of award issuance, stipend/incentive plans must be included in the 'budget justification' section of the ELC budget workbook and receive CDC approval before implementation. After the revised NOA is issued, any subsequent requests for using funds to support stipends/incentives must be made in GrantSolutions, including the stipend/incentive plan, and receive CDC approval before implementation. 13. Resources to complement, but not duplicate, other CDC vaccine delivery efforts (e.g., those activities covered under IP19-1901). Costs can include infrastructure needs (e.g., staff, contractors, call centers, storage, space, etc.) that support testing as well as vaccination operations. 14. Health communications materials and health education services to inform and protect communities are allowable, if they do not duplicate activities covered by other CDC funding mechanisms (e.g., IP21-2106, IP21-2107). Recipients are reminded to be cognizant of the statutory and policy requirements for acknowledging the HHS/CDC funding when issuing statements, press releases, publications, requests for proposal, bid solicitations and other documents. In accordance with CDC General Terms and Conditions for Non -research Awards - Acknowledgement of Federal Funding, in your base award. *Please refer to the allowability roadmap for additional guidance on Colorado LPHA specific allowable costs. 4IPage ELC Enhancing Detection Expansion Guidance - 1/12/2021 15. Expenses associated with outreach and assistance (e.g., support provided through community -based organizations) for those put at higher risk for COVID-19. The above list covers the anticipated, most relevant costs associated with achieving the activities in this guidance. This list does not represent a full list of allowable costs. Recipients are referred to the cost principles regulation found at 45 CFR Part 75 Subpart E — Cost Principles. In determining if costs are allowable, consideration must be given to applicable grant regulations; the overall underlying cooperative agreement (CK19-1904); be considered necessary and reasonable; and be considered allocable (see: 45 CFR 75.403). Any questions about specific budget items should be directed to the OGS and the ELC Project Officer. SUPPORT TO LOCAL HEALTH DEPARTMENTS (LHD) As with previous support provided for COVID-19 activities, recipients should work with their local health departments (LHDs) to determine how local needs will be addressed with the overall available resources. Direct ELC recipients are strongly encouraged to provide financial resources to LHDs within their jurisdiction by way of a contract or other mechanism(s) that may be available through their health department. In addition to financial resources, directly funded recipients may also provide support to LHDs through offering non -financial resources (personnel, supplies, etc.) to address COVID-19/SARS-CoV-2 testing, surveillance, case detection, reporting, response, and prevention needs at the local level. When completing the revised budget, in the ELC budget workbook, there is a state/local health department allocation section that must be completed accurately to allow tracking of direct and indirect support to LHDs. During the quarterly workplan milestone progress reporting, recipients must provide reports, in the REDCap monitoring portal, on progress in supporting LHDs (e.g., on -track or barriers and proposed remedies, etc.) along with amount of funding (direct and/or indirect) to LHDs at time of reporting. The ELC Program Office will continue to monitor spending and programmatic performance, which will be reported to CDC and HHS leadership, and others as appropriate and necessary, on progress and barriers experienced by recipients (see HHS regulation on performance measurement 45 CFR 75.301). Information regarding resources provided to local jurisdictions should be made available to the ELC Project Officer during regular monitoring calls and if issues arise that require action on the part of the recipient or CDC (e.g., significant delays by a local health department when submitting documentation to the state for reimbursement). In circumstances where CDC finds lessons learned from programmatic performance, such as successful or unsuccessful strategies, these may be shared with other recipients. SUPPORTING MANAGEMENT OF ACTIVITIES AND RESOURCES The ELC Program Office strongly recommends that recipients ensure ELC leadership staff at the recipient level are adequate for the management of this award and its integration with the recipient's overall portfolio of ELC funded activities. A minimum of 1 program manager and 1 budget staff (or equivalents) is suggested for the effective management and implementation of the recipients' proposed activities. Depending on the recipient's current capacity for managing both existing COVID-19 funds and these funds associated with this award, the program manager and budget staff may consist of full-time or additional part-time support to achieve the necessary monitoring and management requirements. 5IPage ELC Enhancing Detection Expansion Guidance - 1/12/2021 PROCESS FOR WORKPLAN AND BUDGET SUBMISSION Within five (5) business days of receipt of this guidance the Authorized Official is required to acknowledge receipt of this guidance by submitting a Grant Note in GrantSolutions. The acknowledgement must be submitted on the recipient's official agency letterhead and utilize the 'Acknowledgement Letter for CK19-1904 — COVID Supplemental Funds' template provided at the end of this guidance document. This funding should support activities and the necessary reporting for Budget Period 2 (BP2) under CK19-1904. This supplemental funding is for a 30 1/2 month project period and will end on July 31, 2023. The expanded project period coincides with the end of Budget Period 4 (BP4) of the ELC Cooperative Agreement (CK19-1904); therefore, workplans and revised budgets should reflect activities and associated costs that will end on July 31, 2023. Recipients are reminded that expanded authority3 applies, and funding may be extended to subsequent budget periods to cover the activities until July 31, 2023. Within 60 days of receipt of the Notice of Award (NOA), the recipient is required to submit a workplan and revised budget describing its proposed activities. Upon submission, budgets and workplans will be reviewed by CDC and feedback will be provided and discussed with the recipient. Any necessary or recommended changes may be agreed upon between the recipient and CDC and documented in REDCap; and any agreed upon changes must be captured in GrantSolutions, the system of record, as necessary. To appropriately document workplans, budgets, and facilitate recipients meeting the 60 -day requirement: 1. Workplan entries will be completed in the ELC Enhancing Detection Expansion 'ELC ED Expansion' page, under 'ELC COVID-19 Projects' portal, in REDCap; and 2. Revised budgets must be completed by using the Excel budget workbook template provided via GrantSolutions Grant Notes at time of NOA issuance. Note: If a recipient does not meet the 60 -day submission requirement and has not received written approval for an extension from CDC, then the Payment Management System (PMS) account associated with this award will be restricted. The restriction will result in a manual drawdown process that requires CDC approval of each PMS charge. This restriction will remain in effect until the recipient satisfactorily meets the workplan and budget submission requirement. a. Funds will be awarded under the 'Other' cost category and will be accessible in the Payment Management System (PMS) during the 60 -day budget revision period for use in accomplishing activities outlined in this guidance; b. Recipients will adjust the cost category allocations of awarded funds to reflect the areas where financial assistance is needed; c. Recipients will upload the revised budget into GrantSolutions via a budget revision amendment, with a courtesy copy into REDCap 'ELC ED Expansion Financials' page of the 'ELC COVID-19 Projects' portal, by the 60 -day post award deadline; and d. The ELC Project Officer and OGS will process the budget revision amendment in GrantSolutions and the recipient will receive a revised NOA reflecting the requested cost category allocations. 3. A letter, indicating that all ELC Governance Team members (i.e., Project Director, Epidemiology Lead, Laboratory Lead, Health Information Systems Lead, and Financial Lead) have both contributed to and agreed upon the workplan and revised budget submitted, must be signed by all Governance Team Members (hard copy or digital signature) and submitted with the documents in the REDCap portal. Expanded Authority is provided to recipients through 45 CFR Part 75.308, which allows carryover of unobligated balances from one budget period to a subsequent budget period. Unobligated funds may be used for purposes within the scope of the project as originally approved. Recipients will report use, or intended use, of unobligated funds in Section 12 "Remarks" of the annual Federal Financial Report. 6IPage ELC Enhancing Detection Expansion Guidance - 1/12/2021 Workplan detail Additional workplan guidance will be provided to recipients post -award; they will be required to provide a clear and concise description of the time -bound strategies and activities they will use to achieve the project's outcomes, including: 1. Description of how 'ELC Enhancing Detection Expansion' funding will be used in coordination with funding from CDC's Crisis COVID-19 Notice of Funding Opportunity (NOFO), Immunization and Vaccines for Children cooperative agreement (IP19-1901, original and any COVID-19 supplemental awards), and all other ELC COVID-19 funding previously awarded. 2. Specify the distinct new or enhanced activities made possible by 'ELC ED Expansion'. 3. Plans for how the ELC recipient will work with local jurisdictions to meet local needs that support the entire jurisdiction. These plans must include: description of activities to be supported at the local level, identification of local partners and localities to be supported, methods to assess local needs, and description of funding mechanisms to support local entities, and estimated amount of support (monetary and in -kind) including to local health departments. 4. Description of expected mechanisms and frequency of interactions between the health department and/or public health laboratory with academic/hospital and commercial laboratories. 5. Description of testing and case investigation and contact tracing plan, including populations and institutional settings. Plans should align to your Jurisdictional Testing, Case Investigation, and Contact Tracing plans for COVID-19 per legislation'. Plans for January 2021— December 2021 must be submitted by March 18, 2021; and cover a 1 -year period. The testing and case investigation and contact tracing plan will then be updated, on a quarterly basis, to reflect substantive changes and/or progress. Details about testing and case investigation and contact tracing plan submission will be shared with recipients via the ELC Program Office. a. Please note that HHS and/or CDC may work with recipients to transfer activities and associated costs (e.g., community- based testing sites, large test kit purchases (OASH), etc.) to these funds where appropriate and necessary. b. To the extent that there are existing Federal (HHS) contracts for testing supplies, HHS and/or CDC may work with recipients to consider allowing recipients to buy into those existing contracts, as may be possible under applicable law. 6. Description of use of electronic health systems for surveillance, reporting, and public health action. Note: In a cooperative agreement, CDC staff is substantially involved in the program activities, above and beyond routine grant monitoring. CDC responsibilities include but are not limited to: 1. Provide ongoing guidance, programmatic support (including guidance on evaluation, performance measurement, and workplan changes), technical assistance and subject matter expertise to the activities outlined in this supplemental funding announcement guidance. 2. Convene trainings, meetings, conference calls, and site visits with recipients. 3. Share best practices identified and provide national coordination of activities, where appropriate. 4. Coordinate with the HHS Testing and Diagnostics Working Group, as needed, to support States testing strategies. Within 60 days of receipt of the NOA, the recipient is required to submit a 'Budget Revision Amendment' as part of the recipient's current award (CK19-1904), Budget Period 2, no later than March 18, 2021. 4 Link to bill stating that there is to be a plan and the elements for incorporation: https://www.congress.gov/bill/116th- congress/house-bill/266/ CDC will provide a template in REDCap for recipients to complete to provide additional guidance and ensure all necessary elements are addressed. 71 Page ELC Enhancing Detection Expansion Guidance - 1/12/2021 The 'budget revision amendment' must consist of the following documents: 1. Budget Information: SF -424A a. Recipient can use the form generated by the ELC budget workbook; b. Or, recipient can submit a PDF of this form. c. Please do not use the e -form in GrantSolutions as it creates issues when processing the revised NOA. 2. Cover Letter signed by the Authorized Official of record in GrantSolutions. 3. Completed revised budget using the ELC budget workbook that was provided in GrantSolutions as a Grant Note. REQUIRED TASKS Note: If a recipient does not meet the below required tasks and has not received written approval for an extension from CDC, recipient may have their funds restricted in PMS for specific cost/activities. Recurring or repeat non-compliance may result in additional restrictions or other actions being taken. In addition to the programmatic activities noted below in further detail, recipient responsibilities include but are not limited to: 1. Within five (5) business days of receipt of this guidance the Authorized Official is required to acknowledge receipt of this guidance by submitting a Grant Note in GrantSolutions. The acknowledgement must be submitted on the recipient's official agency letterhead and utilize the 'Acknowledgement Letter for CK19-1904 - COVID Supplemental Funds' template provided at the end of this guidance document. 2. Regular participation in calls with CDC/HHS for technical assistance and monitoring of activities supported through this cooperative agreement. 3. On -time submission of all requisite reporting. This may include but is not limited to reporting of performance measures, progress on milestones, and/or financial updates within REDCap. 4. Report expenditures and unliquidated obligations (ULOs) on a monthly basis. On the 5th day of the month, the expenditures and ULOs from the prior month shall be reported in the REDCap 'ELC ED Expansion Financial Reporting' page. 5. Documentation of any necessary budget change/reallocation through REDCap and, as necessary, GrantSolutions. 6. If implementing new or replacement systems, develop an implementation plan, including: a. Rationale for acquiring a new/replacement health information surveillance system and information used to make the decision, such as i. gaps in existing system ii. options explored prior to making the decision. b. Tasks and efforts required (appropriate milestones). c. Timeline for completion. d. Person responsible for these activities. Implementation plans must be submitted to EDX@cdc.gov, with a copy uploaded into REDCap. Plans will be reviewed and must receive programmatic support from CDC prior to start of implementation. (See Activities section below for specific activities requiring implementation plan and approval.) 7. Schedule a required call (at least 60 minutes) with CDC ELC Health Information Systems (HIS) team to review HIS related activities and milestones described in this workplan. 8. No later than April 30, 2021, have a call with the ELC Project Officer, which will include the recipient representatives to review proposed workplan activities and revised budget submission. 9. Recipient must establish/maintain electronic reporting of SARS-CoV2/COVID-19 laboratory data to CDC daily per the guidance provided by CDC (e.g., CELR). This includes all testing (e.g., positive/negative, PCR, Point -of -Care, etc.) and complete data elements (e.g., race/ethnicity) per CARES legislation and ELC performance measures. 8IPage ELC Enhancing Detection Expansion Guidance - 1/12/2021 Both CDC and recipients should appropriately coordinate with points of contact in relevant stakeholder organizations to maximize the impact of federal dollars [e.g., tribal nations, Health Resources and Services Administration (HRSA), HHS Testing and Diagnostics Working Group, etc.]. ACTIVITIES Data collected as a part of the Activities supported with these funds shall be reported to CDC in the form and fashion determined by CDC. Recipients are required to establish electronic reporting systems to support comprehensive, timely, automated reporting of these data to LHD, CDC and others, at a frequency determined by CDC, if such systems are not already in place. Such systems must support reporting for COVID-19, other conditions of public health significance. Note: These additional resources are intended to be directed toward testing, case investigation and contact tracing, surveillance, containment, and mitigation, including support for workforce, epidemiology, use by employers, elementary and secondary schools, child care facilities, institutions of higher education, long-term care facilities, or in other settings, scale up of testing by public health, academic, commercial, and hospital laboratories, and community -based testing sites, mobile testing units, health care facilities, and other entities engaged in COVID-19 testing, and other related activities related to COVID-19 testing, case investigation and contact tracing, surveillance, containment, and mitigation which may include interstate compacts or other mutual aid agreements for such purposes. The following programmatic workplan activities are required and must be completed by the public health department and/or public health laboratory. Note: If a recipient does not address all the required activities in the workplan, then the workplan will be considered incomplete. If the workplan is not complete by the 60 -day submission requirement, and has not received written approval for an extension from CDC, then the Payment Management System (PMS) account associated with this award will be restricted. The restriction will result in a manual drawdown process that requires CDC approval of each PMS charge. This restriction will remain in effect until the recipient satisfactorily meets the workplan requirement. The 'ELC Enhancing Detection Expansion' workplans will be started in REDCap for recipients through use of the 'ELC Enhancing Detection' workplans. Recipients will then build upon the workplans, in REDCap, to establish their 'ELC Enhancing Detection Expansion' workplans. If activities were not previously addressed in 'ELC Enhancing Detection' workplans, recipients are required to update 'ELC Enhancing Detection Expansion' workplans and respond to all activities. Certain activities or purchases will require recipients to work with ELC HIS prior to the start of implementation. Enhance Laboratory, Surveillance, Informatics and other Workforce Capacity 1. Train and hire staff to improve laboratory workforce ability to address issues around laboratory safety, quality management, inventory management, specimen management, diagnostic and surveillance testing and reporting results. 2. Build expertise for healthcare and community outbreak response and infection prevention and control (IPC) among local health departments. 3. Train and hire staff to improve the capacities of the epidemiology and informatics workforce to effectively conduct surveillance and response of COVID-19 (including case investigation and contact tracing) and other emerging infections and conditions of public health significance. This should include staff who can address unique cultural needs of those put at higher risk for COVID-19. 4. Build expertise to support management of the COVID-19 related activities within the jurisdiction and integrate into the broader ELC portfolio of activities (e.g., additional leadership, program and project managers, budget staff, etc.). 5. Increase capacity for timely data management, analysis, and reporting for COVID-19 and other emerging coronavirus and other infections and conditions of public health significance. 9IPage ELC Enhancing Detection Expansion Guidance - 1/12/2021 Strengthen Laboratory Testing 1. Establish or expand capacity to quickly, accurately and safely test for SARS-CoV-2/COVID-19 and build infectious disease preparedness for future coronavirus and other events involving other pathogens with potential for broad community spread. a. Develop systems to improve speed and efficiency of specimen submission to clinical and reference laboratories. b. Strengthen ability to quickly scale testing [e.g., nucleic acid amplification test (NAAT), antigen, etc.] as necessary to ensure that optimal utilization of existing and new testing platforms can be supported to help meet increases in testing demand in a timely manner. Laboratories are strongly encouraged to diversify their testing platforms to enable them to pivot depending on reagent and supply availabilities. c. Perform serology testing with an FDA EUA authorized serological assay in order to conduct surveillance for past infection and monitor community exposure. d. Work with LHDs, including through sub -awards, to build local capacity for testing of COVID-19/SARS-CoV-2 including within high -risk settings or in vulnerable populations that reside in their communities. e. Apply laboratory safety methods to ensure worker safety when managing and testing samples that may contain SARS-CoV-2/COVID-19. f. Implement alternative surveillance methods, including sequencing, wastewater surveillance, regional testing centers for surveillance and screening, etc. and link with other relevant surveillance systems (e.g., immunization registry). [This activity is optional and should complement other already funded activities.] g. Augment or add specificity to existing laboratory response plans for future coronavirus and other outbreak responses caused by an infectious disease. h. Support national surveillance for SARS-CoV-2 by submitting representative, deidentified samples to CDC for sequencing through the National SARS-CoV-2 Strain Surveillance (NS3) program. Note: CDC has issued guidance elsewhere on specifics of the submission of samples and metadata (see https://www.aphl.org/sars2seq), but in general: unless otherwise indicated, samples submitted for NS3 should be from separate cases, unrelated to each other and that represent typical cases of COVID-19 in the jurisdiction. The number of samples requested is reflective of a minimum number of samples needed for long term surveillance, with adjustments for population and other factors. Please work with the CDC NS3 surveillance team to develop a sustainable sampling plan for your jurisdiction. i. Expand the use of SARS-CoV-2 genomic sequencing and molecular epidemiology for state and local surveillance and response. Note: Timely access to viral genomic sequence data can be a critically important tool in responding to outbreaks; assessing transmission pathways, mechanisms and risk; determining the effectiveness of public health control measures; positioning state and local public health resources; and in supporting policy decisions. CDC encourages the expanded role of sequence data in support of state, local and regional public health priorities, especially when they are done in coordination with national sequencing efforts such as SARS-CoV-2 Sequencing for Public Health Emergency Response, Epidemiology and Surveillance (SPHERES). These efforts could include rapid sequencing and analysis of SARS-CoV-2 genomes by contractors and staff within the public health laboratory itself, through the expansion of laboratory capacity, workforce or bioinformatics capabilities (including improved access to cloud computing resources), or through the establishment or expansion of partnerships with academia and the private sector. 2. Enhance laboratory testing capacity for SARS-CoV-2/COVID-19 outside of public health laboratories a. Conduct surveillance of all SARS-CoV-2/COVID-19 testing resources and map the jurisdictional testing resources that exist outside the public health arena (e.g., point of care, private, academic, etc.). 10IPage ELC Enhancing Detection Expansion Guidance - 1/12/2021 b. Establish or expand capacity to coordinate with public/private laboratory testing providers, including those that assist with surge and with testing for high -risk environments. c. Secure and/or utilize mobile laboratory units, or other methods to provide POC testing (including antigen testing) at public health -led clinics or non-traditional test sites including but not limited to shelters or other places of congregate housing, food processing plants, correctional facilities, Long Term Care Facilities (LTCF), elementary and secondary schools, child care facilities, and institutions of higher education. d. Ensure public/private laboratory testing providers, including those providing POC testing at public health - led clinics or non-traditional test sites, are provided biosafety resources for SARS-CoV-2 specimen collection and/or testing. 3. Enhance data management and analytic capacity in public health laboratories to help improve efficiencies in operations, management, testing, and data sharing. a. Improve efficiencies in laboratory operations and management using data from throughput, staffing, billing, supplies, and orders. Ensure ability to track inventory of testing reagents by device/platform, among other things. b. Improve the capacity to analyze laboratory data to help understand and make informed decisions about issues such as gaps in testing and community mitigation efforts. Data elements such as tests ordered and completed (including by device/platform), rates of positivity, source of samples, specimen collection sites, and test type will be used to create data visualizations that will be shared with the public, local health departments, and federal partners. Advance Electronic Data Exchange at Public Health Labs 1. Enhance and expand laboratory information infrastructure, to improve jurisdictional visibility on laboratory data (tests performed) from all testing sites and enable faster and more complete data exchange and reporting. a. Employ a well -functioning Laboratory Information Management System (LIMS) system to support efficient data flows within the PHL and its partners. This includes expanding existing capacity of the current LIMS to improve data exchange and increase data flows through LIMS maintenance, new configurations/modules, and enhancements. Implement new/replacement LIMS where needed. Note: If implementing new or replacement systems, develop an implementation plan, including appropriate milestones and timeline to completion. Implementation plans will be reviewed and approved for consistency with the activities set forth in the ELC awards by CDC prior to start of implementation. b. Ensure ability to administer LIMS. Ensure the ability to configure all tests that are in LIMS, including new tests, EUAs, etc., in a timely manner. Ensure expanding needs for administration and management of LIMS system are covered through dedicated staff. c. Interface diagnostic equipment to directly report laboratory results into LIMS. d. Put a web portal in place to support online ordering and reporting. Integrate the web portal into the LIMS. Note: If implementing new or replacement systems, develop an implementation plan, including appropriate milestones and timeline to completion. Implementation plans will be reviewed and approved for consistency with the activities set forth in the ELC awards by CDC prior to start of implementation. e. Enhance laboratory test ordering and reporting capability. i. Implement or improve capacity to consume and produce electronic HL7 test orders and result reporting (ETOR) to allow laboratories and healthcare providers to directly exchange 11IPage ELC Enhancing Detection Expansion Guidance - 1/12/2021 standardized test orders and results across different facilities and electronic information systems using agreed upon standards. ii. 100% of results must be reported with key demographic variables including age/gender/race. iii. Report all testing to the health department and CDC using HL7 ELR. Improve Surveillance and Reporting of Electronic Health Data Conducting the activities in this section to enable comprehensive, automated, daily reporting to the CDC and others in a machine-readable format, is a requirement of accepting these funds. See CDC website(s) for required data elements. Websites will be amended as requirements are updated. A. Lab Reporting: https://www.cdc.qov/coronavirus/2019-ncov/lab/reporting-lab-data.html#what-to-report B. Case Reporting: https://www.cdc.gov/coronavirus/2019-ncov/php/reporting-pui.html. 1. Establish complete, up-to-date, timely, automated reporting of morbidity and mortality to CDC and others due to COVID-19 and other coronavirus and other emerging infections which impact conditions of public health significance, with required associated data fields in a machine-readable format, by: a. Establishing or enhancing community -based surveillance, including surveillance of vulnerable populations, individuals without severe illness, those with recent travel to high -risk locations, or who are contacts to known cases. b. Monitoring changes to daily incidence rates of COVID-19 and other conditions of public health significance at the county or zip code level to inform community mitigation strategies. 2. Establish additional and on -going surveillance methods (e.g. sentinel surveillance) for COVID-19 and other conditions of public health significance. 3. Establish complete, up-to-date, timely, automated reporting of individual -level data through electronic case reporting to CDC and others in a machine-readable format (ensuring LHD have access to data that is reported): a. At the health department, enhance capacity to work with testing facilities to onboard and improve electronic laboratory reporting (ELR), including to receive data from new or non-traditional testing settings. Use alternative data flows (e.g., reporting portals) and file formats (e.g., CSV or XLS) to help automate where appropriate. In addition to other reportable results, this should include all COVID- 19/SARS-CoV-2-related testing data (i.e., tests to detect SAR-CoV-2 including serology testing). b. Automate receiving EHR data, including eCR and FHIR-base eCR Now, to generate initial case report as specified by CDC for the reportable disease within 24 hours and to update over time within 24 hours of a change in information contained in the CDC -directed case report, including death. Utilize eCR data to ensure data completeness, establish comprehensive morbidity and mortality surveillance, and help monitor the health of the community and inform decisions for the delivery of public health services. c. Develop a project plan for the automated processing of the Electronic Initial Case Report (eICR) and Reportability Response (RR) into health information systems. Prior to implementation of eICR and RR for a specific disease or disease group, plan how data will be used for surveillance workflows (e.g. negative COVID-19 reports from providers), draft reporting specifications, and consumption, as appropriate. Note: As an interim solution, while health information system capacity is being developed, convert to a human readable format and provide for use by appropriate surveillance program personnel. 12IPage ELC Enhancing Detection Expansion Guidance - 1/12/2021 d. Increase connectivity with laboratory and healthcare feeds for epidemiologic analysis (including using automated single CSV files). e. Expand electronic reporting mechanism (e.g., eCR, ELR) to include all conditions of public health significance. 4. Improve understanding of capacity, resources, and patient impact at healthcare facilities through electronic reporting. a. Required expansion of reporting facility capacity, resources, and patient impact information, such as patients admitted and hospitalized, in an electronic, machine-readable, as well as human -readable visual, and tabular manner, to achieve 100% coverage in jurisdiction and include daily data from all acute care, long-term care, and ambulatory care settings. Use these data to monitor facilities with confirmed cases of COVID-19/SARS-CoV-2 infection or with COVID-like illness among staff or residents and facilities at high risk of acquiring COVID-19/SARS-CoV-2 cases and COVID-like illness among staff or residents. b. Increase ADT messaging and use to achieve comprehensive surveillance of emergency room visits, hospital admissions, facility and department transfers, and discharges to provide an early warning signal, to monitor the impact on hospitals, and to understand the growth of serious cases requiring admission. 5. Enhance systems for flexible data collection, reporting, analysis, and visualization. a. Implement new/replacement systems where needed. Ensure systems are interoperable and that data can be linked across systems (e.g., public health, healthcare, private labs), including adding the capacity for lab data and other data to be used by the software/tools that are being deployed for case investigation and contact tracing. Note: 1. If implementing new or replacement systems, develop an implementation plan, including: a. Rationale for acquiring a new/replacement health information surveillance system and information used to make the decision, such as i. gaps in existing system ii. options explored prior to making the decision. b. Tasks and efforts required (appropriate milestones). c. Timeline for completion. d. Person responsible for these activities. Implementation plans must be submitted to EDX@cdc.gov, with a copy uploaded into REDCap. Plans will be reviewed and must receive programmatic support from CDC prior to start of implementation. 2. Examples for data linkages and/or interoperability across systems include case surveillance data, vaccination data, vital records, etc. 3. If implementing or expanding immunizations related information technology systems (e.g., registries, data lake, YAMS, vaccine finder, etc.), recipient should work with Immunization Cooperative Agreement Project Officer for long-term support. Once COVID funds are exhausted, ELC Cooperative Agreement will not have resources for ongoing financial assistance with these registries. 13 IPage ELC Enhancing Detection Expansion Guidance - 1/12/2021 b. Update/Enhance/Modernize infrastructure to handle large data streams and properly process, triage, and retain data. For example, receiving large numbers of negative test results, triage, process, and use as appropriate. Consider scalable storage (e.g. data lake). c. Data must be made available at the local, state, and federal level. d. Make data on cases, syndromic surveillance, laboratory tests, hospitalization, and healthcare capacity available on health department websites at the county/zip code level in a visual and tabular manner. 6. Establish or improve systems to ensure complete, accurate and immediate (within 24 hrs.) data transmission to a system and open website available to local health officials and the public by county and zip code, that allows for automated transmission of data to the CDC in a machine readable format. a. Increase coverage (Target for emergency departments (ED): 100%) and number of facilities submitting syndromic surveillance data to the National Syndromic Surveillance Program (NSSP) [https://www.cdc.gov/nssp/index.html] for emergency department (ED) and urgent care facilities for syndromes and illnesses with messages that include the NSSP priority 1 and 2 data elements. b. Submit all case reports in an immediate, automated way to CDC for COVID-19/SARS-CoV-2 and other conditions of public health significance with associated required data fields in a machine-readable format. c. Provide accurate accounting of COVID-19/SARS-CoV-2 associated deaths. Establish electronic, automated, immediate death reporting to CDC with associated required data fields in a machine- readable format. d. Report requested COVID-19/SARS-CoV-2-related data, including line level testing data (negatives, positives, indeterminants, serology, antigen, nucleic acid) daily by county or zip code to the CDC - designated system. e. Establish these systems in such a manner that they may be used on an ongoing basis for surveillance of, and reporting on, routine and other threats to the public health and conditions of public health significance. Use Laboratory Data to Enhance Investigation, Response and Prevention 1. Use laboratory data to initiate and conduct case investigation and contact tracing and follow up; and implement containment measures. a. Conduct necessary case investigation and contact tracing including contact elicitation/identification, contact notification, contact testing, and follow-up. Activities could include traditional case investigation and contact tracing and/or proximity/location-based methods, as well as methods adapted for healthcare -specific contexts, employers, elementary and secondary schools, childcare facilities, institutions of higher education, long-term care facilities, or in other settings. b. Utilize tools (e.g., geographic information systems and methods) that assist in the rapid mapping and tracking of disease cases for timely and effective epidemic monitoring and response, incorporating laboratory testing results and other data sources. 2. Identify cases and exposure to COVID-19 in high -risk settings or within populations at increased risk of severe illness or death to target mitigation strategies and referral for therapies (for example, monoclonal antibodies) to prevent hospitalization. a. Assess and monitor infections in healthcare workers across the healthcare spectrum. b. Monitor cases and exposure to COVID-19 to identify need for targeted mitigation strategies to isolate and prevent further spread within high -risk healthcare facilities (e.g., hospitals, dialysis clinics, cancer clinics, nursing homes, and other long-term care facilities, etc.). 14IPage ELC Enhancing Detection Expansion Guidance - 1/12/2021 c. Monitor cases and exposure to COVID-19 to identify need for targeted mitigation strategies to isolate and prevent further spread within high -risk occupational settings (e.g., meat processing facilities), and congregate living settings (e.g., correctional facilities, youth homes, shelters). d. Work with LHDs to build local capacity for reporting, rapid containment and prevention of COVID- 19/SARS-CoV-2 within high -risk settings or in vulnerable populations that reside in their communities. e. Jurisdictions should ensure systems are in place to link test results to relevant public health strategies, including prevention and treatment. Note: Additional resources Treatment: https://www.cdc.gov/coronavirus/2019-ncov/your-health/treatments-for- severe-illness.html Public health strategies: https://www.cdc.gov/mmwr/volumes/69/wr/mm6949e2.htm 3. Implement prevention strategies in high -risk settings or within vulnerable populations (including tribal nations as appropriate) including proactive monitoring for asymptomatic case detection. Note: These additional resources are intended to be directed toward testing, case investigation and contact tracing, surveillance, containment, and mitigation, including support for workforce, epidemiology, use by employers, elementary and secondary schools, child care facilities, institutions of higher education, long- term care facilities, or in other settings, scale up of testing by public health, academic, commercial, and hospital laboratories, and community -based testing sites, mobile testing units, health care facilities, and other entities engaged in COVID-19 testing, and other related activities related to COVID-19 testing, case investigation and contact tracing, surveillance, containment, and mitigation which may include interstate compacts or other mutual aid agreements for such purposes. a. Build capacity for infection prevention and control in LTCFs (e.g., at least one Infection Preventionist (IP) for every facility) and outpatient settings. i. Build capacity to safely house and isolate infected and exposed residents of LTCFs and other congregate settings. ii. Develop interoperable patient safety information exchange systems. iii. Assist with enrollment of all LTCFs into NHSN and provision of related user support. b. Build capacity for infection prevention and control in elementary and secondary schools, childcare facilities, and/or institutions of higher education. c. Increase Infection Prevention and Control (IPC) assessment capacity onsite using tele-ICAR. d. Perform preparedness assessment to ensure interventions are in place to protect high -risk populations. e. Coordinate as appropriate with federally funded entities responsible for providing health services to higher -risk populations (e.g., tribal nations and federally qualified health centers). Coordinate and Engage with Partners 1. Partner with LHDs to establish or enhance testing for COVID-19/SARS-CoV-2. a. Support appropriate LHDs with acquiring equipment and staffing to conduct testing for COVID- 19/SARS-CoV-2. b. Support LHDs to conduct appropriate specimen collection and/or testing within their jurisdictions. 2. Partner with local, regional, or national organizations or academic institutions to enhance capacity for infection control and prevention of COVID-19/SARS-CoV-2. 15 I P a g e ELC Enhancing Detection Expansion Guidance - 1/12/2021 a. Build infection prevention and control and outbreak response expertise in local health departments (LHDs). b. Partner with academic medical centers and schools of public health to develop regional centers for IPC consultation and support services. PERFORMANCE MEASURES AND REPORTING Performance Measures: In addition to the metrics and deliverable indicated above, performance measures specific to COVID-19-related activities will be finalized and provided to recipients within approximately 45 days of award. The ELC Program Office will utilize existing data sources whenever possible to reduce the reporting burden on recipients and, where appropriate, existing ELC performance measures may be used. While more frequent reporting may be employed within the first year of this supplement, these requirements may be adjusted as circumstances allow. Where it is possible, reporting will be aligned to current performance measure reporting timelines. Consistent with current ELC Program Office practice, progress on workplan milestones will be reported on a quarterly basis utilizing REDCap. Recipients will be provided 2 weeks to update their progress and note any challenges encountered since the previous update. Financial reporting requirements shall be noted and, as necessary, updated in the Terms and Conditions of the award. The ELC Program Office will work with OGS to limit the administrative burden on recipients. Summary of Reporting Requirements: 1. Quarterly progress reports on milestones in approved workplans via REDCap. 2. Monthly fiscal reports (beginning 60 days after NOAs are issued). 3. Performance measure data. 4. CDC may require recipients to develop annual progress reports (APRs). CDCwill provide APR guidance and optional templates should they be required. Please also note: Data collected as a part of the activities supported with these funds shall be reported to CDC in a form and fashion to be determined and communicated at a later date. 16IPage (bW/A'N.N/.b40/1M/NON//.WC/N/A.YN/N.(b/r 4JNrvW'N// l./bP//%� ELC Enhancing Detection Expansion ELC Enhancing Detection Expansion Guidance - 1/12_/2021 ACKNOWLEDGEMENT LETTER: DUE WITHIN FIVE (5) DAYS OF NOA RECEIPT Date: JUL 1 4 2021 Organization Name: Subject: Acknowledgement Letter for CK19-1904 — COVID-19 Supplemental Funds Reference: Guidance for the use of supplemental funding (January 2021) for CK19-1904 ELC Enhancing Detection Through Coronavirus Response and Relief (CRR). This is to acknowledge that I have received, reviewed and understand the requirements in the attached programmatic guidance. The federal funding received will be in support of the supplemental funding referenced herein and will be spent in accordance with the legislation and programmatic guidance. Authorized Official Steve Moreno, BOCC Chair l 'JUL 1 4 2021 021 17I Page :%////M/////.H4094SGNA9KY/d////H/SAW/N/A➢XC//f/SO///4tY/r,Y///M/A'dS///aroM4F++' IWXZ vASS/u//. OiW/I1WM/GKM'WMIXVOZYS/ACC474IXWF�ZGGgAXSKM.[AX//[M.dk KStie*C lbh.IdleV S%N.G# 000707/Z4b4MX4T1/MW/G///HVAS4ZS k6YORWM$4,00C biY/M.4WM OV.e.ie407X^ S[4AT40h#]Yb//MM404bKY//H.4%W.W SSYf5.NWFb.6.VkY4CSOWC/ACHS407/dMF.^�..cWFrY,tCYA tiro%/?///4".?n/F.Y.%F/. P=COW.X/.Htre4 400:.f9/l.a4V4740 49A.YAdb%.(Yi r407/XWA /ord //rri/F/aYAW 0 Contract Form New Contract Request Entity Information Entity Name'* COLORADO DEPT OF PUBLIC HEALTH 'ENVIRONMENT Entity ID* 000©1926 Contract Name* Contract ID CDPHE ELC ENHANCING DETECTION EXPANSION ROUND 2 4961 ACKNOWLEDGEMENT LETTER Contract Lead* Contract Status BMANRIQUEZ CTB REVIEW Contract Lead Email bmanriquez gweldg•ov.com Contract Description* ELC ENHANCING DETECTION EXPANSION FOR COVID-19 ROUND 2 WITH CDPHE Contract Description 2 Contract Type* Departrent STATEMENT OF WORK HEALTH Amount * X5,937,731 .00 Renewable* NO Automatic Renewal NO Grant YES IGA NO Department Email CM -Health _'eldgay.com Department H a Email CM -Health - De ptHead.ve I d g o v. co m County Attorney GENERAL COUNTY Al I ORNEY EMAIL County Attorney Email CM- COUNTYATTORNEY. WELDG OV.COM Requested BOCC Agenda Date* 07? 14 2021 Parent Contract ID Requires YES d Department Project # Due Date 07x'10,2021 Will a work session with BOCC be required?* NO Does Contract require Purchasing Dept. to be included? NO Grant Deadline Date If this is a renewal enter previous Contract ID If this is part of a MSA enter MSA Contract ID Note: the Previous Contract Number and Master Services Agreement Number should be left blank if those contracts are not in On Base Contract Dates Effective Date 05 10 2021 Review Date * 04 01 2022 Renewal Date Termination Notice Period Committed Delivery Date Contact Information Contact Info Contact Name Purchasing Expiration Date • 07;31,2023 Contact Type Contact Email Contact Phone 1 Contact Phone 2 Purchasing Approver Purchasing Approved Date Approval Process Department Head TANYA GEISER DH Approved Date 07:06 2021 Final Approval BOCC Approved BOCC Signed Date BOCC Agenda Date 07:14/2021 Originator BMANRIQUEZ Finance Approver CHRIS D'OVIDIO Legal Counsel KARIN MCDOUGAL Finance Approved Date Legal Counsel Approved Date 07.0712021 07,`07,32021 Tyler Ref # AG 071421 Hello